Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy

Documenti analoghi

• Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
  di: Weixian Hu
  Pubblicazione: (2020-01-01)
• Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
  di: Tan, Wei Chang Colin, et al.
  Pubblicazione: (2020)
• Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma
  di: Coy, Shannon, et al.
  Pubblicazione: (2018)
• Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
  di: Kudo, Masatoshi
  Pubblicazione: (2019)
• CRAN-11. MULTIPLEXED IMMUNOFLUORESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA
  di: Coy, Shannon, et al.
  Pubblicazione: (2018)